Translating pharmacogenetics into clinical practice: Interleukin (IL)28B and inosine triphosphatase (ITPA) polymophisms in hepatitis C virus (HCV) infection

Clinical Chemistry and Laboratory Medicine

Volumn 49, Issue 8, 2011, Pages 1247-1256

  Cariani, Elisabetta ^a   Villa, Erica ^b   Rota, Cristina ^a   Critelli, Rosina ^b   Renti, Tommaso ^a  

^a Ospedale Civile S Agostino Estense   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

hepatitis C virus (HCV); inosine triphosphatase (ITPA); interferon (IFN); interleukin 28B (IL28B); polymorphism (SNP); ribavirin (RBV)

Indexed keywords

DRUG METABOLITE; INOSINE TRIPHOSPHATASE; INTERFERON; INTERLEUKIN 28B; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PHOSPHATASE; RIBAVIRIN; RIBAVIRIN TRIPHOSPHATE; UNCLASSIFIED DRUG;

BONE MARROW TOXICITY; CLINICAL DECISION MAKING; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEMOLYTIC ANEMIA; HEPATITIS C; HIGH RISK PATIENT; HUMAN; PATIENT IDENTIFICATION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRAL CLEARANCE; VIRUS LOAD;

ANTIVIRAL AGENTS; GENOME-WIDE ASSOCIATION STUDY; HEPATITIS C; HUMANS; INTERLEUKINS; POLYMORPHISM, SINGLE NUCLEOTIDE; PYROPHOSPHATASES;

HEPATITIS C VIRUS;

EID: 80051766104     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2011.618     Document Type: Review

References (102)

1. Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004;44: 20-9.
2. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol 2003;36:47-53.
3. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 1999; 341:556-62.
4. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-14. (Pubitemid 46780630)
5. Campello C, Poli A, Dal MG, Besozzi-Valentini F. Seroprevalence, viremia and genotype distribution of hepatitis C virus: A community-based population study in northern Italy. Infection 2002;30:7-12. (Pubitemid 34146405)
6. Sagnelli E, Stroffolini T, Mele A, Almasio P, Coppola N, Ferrigno L, et al. The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. J Med Virol 2005;75:522-7. (Pubitemid 40293519)
7. Bowden DS, Berzsenyi MD. Chronic hepatitis C virus infection: Genotyping and its clinical role. Future Microbiol 2006;1: 103-12.
8. Martinot-Peignoux M, Roudot-Thoraval F, Mendel I, Coste J, Izopet J, Duverlie G, et al. Hepatitis C virus genotypes in France: Relationship with epidemiology, pathogenicity and response to interferon therapy. The GEMHEP. J Viral Hepat 1999;6:435-43.
9. Roffi L, Ricci A, Ogliari C, Scalori A, Minola E, Colloredo G, et al. HCV genotypes in Northern Italy: A survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998; 29:701-6. (Pubitemid 28505925)
10. Zeuzem S. Interferon-based therapy for chronic hepatitis C: Current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008;5:610-22.
11. Poynard T, McHutchison J, Goodman Z, Ling MH, Albrecht J. Is an ''a la carte'' combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology 2000;31:211-8. (Pubitemid 30033709)
12. Charlton M, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-86. (Pubitemid 43980094)
13. Negro F. Mechanisms and significance of liver steatosis in hepatitis C virus infection. World J Gastroenterol 2006;12:6756-65. (Pubitemid 44811395)
14. Roffi L, Colloredo G, Pioltelli P, Bellati G, Pozzpi M, Parravicini P, et al. Pegylated interferon-alpha2b plus ribavirin: An efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosis. Antivir Ther 2008;13:663-73.
15. Villa E, Karampatou A, Cammá C, Di Leo A, Luongo M, Ferrari A, et al. Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C. Gastroenterology 2011;140:818-29.
16. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
17. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to PEGylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
18. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009;41:1100-4.
19. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
20. Rauch A, Kutalik Z, Descombes P, Cai T, Di IJ, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: A genome-wide association study. Gastroenterology 2010;138:1338-45.
21. McCarthy JJ, Li JH, Thompson A, Suchindran S, Lao XQ, Patel K, et al. Replicated association between an IL28B gene variant and a sustained response to PEGylated interferon and ribavirin. Gastroenterology 2010;138:2307-14.
22. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010;139:120-9.
23. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, Shianna KV, et al. ITPA gene variants protect against anemia in patients treated for chronic hepatitis C. Nature 2010;464:405-8.
24. Tillmann HL, Thompson AJ, Patel K, Wiese M, Tenckhoff H, Nischalke HD, et al. A polymorphism near IL28B is associated with spontaneous clearance of acute hepatitis C virus and jaundice. Gastroenterology 2010;139:1586-92.
25. Montes-Cano MA, García-Lozano JR, Abad-Molina C, Romero-Gómez M, Barroso N, Aguilar-Reina J, et al. Interleukin-28B genetic variants and hepatitis virus infection by different viral genotypes. Hepatology 2010;52:33-7.
26. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to PEGylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. J Hepatol 2011;54:439-48.
27. Sarrazin C, Susser S, Doehring A, Lange CM, Müller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011;54:415-21.
28. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-7.
29. Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, et al. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol 2011;9:344-50.
30. Kawaoka T, Hayes CN, Ohishi W, Ochi H, Maekawa T, Abe H, et al. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J Hepatol 2011;54:408-14.
31. Barrera JM, Bruguera M, Ercilla MG, Gil C, Celis R, Gil MP, et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995;21:639-44.
32. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: A tale of coevolution and coexistence. J Clin Invest 2009;119:1745-54.
33. Post J, Ratnarajah S, Lloyd AR. Immunological determinants of the outcomes from primary hepatitis C infection. Cell Mol Life Sci 2009;66:733-56.
34. Balagopal A, Thomas DL, Thio CL. IL28B and the control of hepatitis C virus infection. Gastroenterology 2010;139:1865-76.
35. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, et al. Variants in IL28B in liver recipients and donors correlate with response to PEG-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010;139:1577-85.
36. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with PEGinterferon and ribavirin. Hepatology 2010;52:421-9.
37. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, et al. Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. AIDS 2010;24:F23-9.
38. Aparicio E, Parera M, Franco S, Pérez-Alvarez N, Tural C, Clotet B, et al. IL28B SNP rs8099917 is strongly associated with PEGylated interferon-a and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One 2010; 5:e13771.
39. Pineda JA, Caruz A, Rivero A, Neukam K, Salas I, Camacho A, et al. Prediction of response to PEGylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 2010;51:788-95.
40. Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, et al. Modeling the probability of sustained virological response to therapy with PEGylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010;51:1209-16.
41. Lampertico P, Viganó M, Cheroni C, Facchetti F, Valveri V, Soffredini R, et al. Genetic variation in IL28B polymorphism may predict HBsAg clearance in genotype D, HBeAg negative patients treated with interferon alfa wabstractx. Hepatology 2010;52:442A.
42. Martin MP, Qi Y, Goedert JJ, Hussain SK, Kirk GD, Hoots WK, et al. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J Infect Dis 2010;202: 1749-53.
43. Kamatani Y, Wattanapokayakit S, Ochi H, Kawaguchi T, Takahashi A, Hosono N, et al. A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. Nat Genet 2009;41:591-5.
44. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007;317:944-7. (Pubitemid 47301321)
45. The International HapMap Consortium. The international hapmap consortium: A haplotype map of the human genome. Nature 2005;437:1299-320.
46. Abe H, Ochi H, Maekawa T, Hayes N, Tsuge M, Miki D, et al. Common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients. J Hepatol 2010;53:439-43.
47. Li JH, Lao XQ, Tillmann HL, Rowell J, Patel K, Thompson A, et al. Interferon-lambda genotype and low serum low-density lipoprotein cholesterol levels in patients with chronic hepatitis C infection. Hepatology 2010;51:1904-11.
48. Lindh M, Lagging M, Norkrans G, Hellstrand K. A model explaining the correlations between IL28B-related genotypes, hepatitis C virus genotypes, and viral RNA levels. Gastroenterology 2010;139:1794-6.
49. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomicbased treatment paradigms for patients with chronic hepatitis C infection: The future of personalized HCV therapies. Am J Gastroenterol 2011;106:38-45.
50. Meyer MF, Lehmann M, Cornberg M, Wiegand J, Manns MP, Klade C, et al. Clearance of low-levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007; 4:58.
51. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: The modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009;86:23-32.
52. Witte K, Witte E, Sabat R, Wolk K. IL-28A, IL-28B, and IL-29: Promising cytokines with type I interferon-like properties. Cytokine Growth Factor Rev 2010;21:237-51.
53. Fox BA, Sheppard PO, O'Hara PJ. The role of genomic data in the discovery, annotation and evolutionary interpretation of the interferon-lambda family. PLoS One 2009;4:e4933.
54. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006;131: 1887-98. (Pubitemid 44958521)
55. Muir AJ, Shiffman ML, Zaman A, Yoffe B, de la Torre A, Flamm S, et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010;52:822-32.
56. Urban TJ, Thompson AJ, Bradrick SS, Fellay J, Schuppan D, Cronin KD, et al. IL28B genotype is associated with differential expression of intrahepatic interferon-stimulated genes in patients with chronic hepatitis C. Hepatology 2010;52: 1888-96.
57. Honda M, Sakai A, Yamashita T, Nakamoto Y, Mizukoshi E, Sakai Y, et al. Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C. Gastroenterology 2010;139:499-509.
58. Abe H, Hayes N, Ochi H, Maekawa T, Tsuge M, Miki D, et al. IL28B variation affects expression of interferon stimulated genes and effect of PEG-interferon and ribavirin therapy. J Hepatol 2011 Feb 4. wEpub ahead of printx.
59. Chen L, Borozan I, Feld J, Sun J, Tannis LL, Coltescu C, et al. Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection. Gastroenterology 2005;128:1437-44. (Pubitemid 40712193)
60. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN, et al. Hepatic gene expression during treatment with PEGinterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007;46:1548-63. (Pubitemid 350155537)
61. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W, et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008;105:7034-9. (Pubitemid 351754525)
62. Dill MT, Duong FH, Vogt JE, Bibert S, Bochud PY, Terracciano L, et al. Interferon-induced gene expression is a stronger predictor of treatment response than IL28B genotype in patients with hepatitis C. Gastroenterology 2011;140:1021-31.
63. Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: Translating pharmacogenomics into clinical practice. J Gastroenterol 2010;45:903-10.
64. Rauch A, Rohrbach J, Bochud PY. The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 2010;40:950-9.
65. Thio CL, Thomas DL. Interleukin-28b: A key piece of the hepatitis C virus recovery puzzle. Gastroenterology 2010;138: 1240-3.
66. Mordstein M, Michiels T, Staeheli P. What have we learned from the IL28 receptor knockout mouse? J Interferon Cytokine Res 2010;30:579-84.
67. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology 2011;53:336-5.
68. Patterson JL, Fernandez-Larsson R. Molecular mechanisms of action of ribavirin. Rev Infect Dis 1990;12:1132-46.
69. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet 1991;337:1058-61.
70. Di Bisceglie AM, Shindo M, Fong TL, Fried MW, Swain MG, Bergasa NV, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16:649-54.
71. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seeff LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: A multicenter trial. Hepatology 1997; 26:473-7. (Pubitemid 27328328)
72. Tanabe Y, Sakamoto N, Enomoto N, Kurosaki M, Ueda E, Maekawa S, et al. Synergistic inhibition of intracellular hepatitis C virus replication by combination of ribavirin and interferon-alpha. J Infect Dis 2004;189:1129-39. (Pubitemid 38457235)
73. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trepo C, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1493-9. (Pubitemid 28543497)
74. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339:1485-92. (Pubitemid 28543496)
75. Crotty S, Maag D, Arnold JJ, Zhong W, Lau JY, Hong Z, et al. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000;6:1375-9. (Pubitemid 32001022)
76. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates the T helper (Th) 1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-91. (Pubitemid 28464295)
77. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with PEGinterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-38.
78. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. PEGinterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001;358:958-65. (Pubitemid 32913521)
79. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL, et al. PEGinterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-82.
80. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and PEGinterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009;360:1839-50.
81. Suzuki F, Akuta N, Suzuki Y, Sezaki H, Yatsuji H, Kawamura Y, et al. Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), PEGylated interferon and ribavirin for 12 weeks. Hepatol Res 2009;39:1056-63.
82. De Franceschi L, Fattovich G, Turrini F, Ayi K, Brugnara C, Manzato F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: Role of membrane oxidative damage. Hepatology 2000;31:997-1004. (Pubitemid 30169949)
83. Nomura H, Tanimoto H, Kajiwara E, Shimono J, Maruyama T, Yamashita N, et al. Factors contributing to ribavirin-induced anemia. J Gastroenterol Hepatol 2004;19:1312-7. (Pubitemid 39481767)
84. Takaki S, Tsubota A, Hosaka T, Akuta N, Someya T, Kobayashi M, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004;39:668-73. (Pubitemid 39149355)
85. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L. Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anemia. J Viral Hepat 2004;11:84-7. (Pubitemid 38221622)
86. Van Vlierbergh H, Delanghe JR, De Vos M, Leroux-Roel G, BASL Steering Committee. Factors influencing ribavirininduced hemolysis. J Hepatol 2001;34:911-6.
87. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002;111: 360-7. (Pubitemid 36075062)
88. Shipkova M, Lorenz K, Oellerich M, Wieland E, von Ahsen N. Measurement of erythrocyte inosine triphosphate pyrophosphohydrolase (ITPA) activity by HPLC and correlation of ITPA genotype-phenotype in a Caucasian population. Clin Chem 2006;52:240-7. (Pubitemid 43185485)
89. Atanasova S, Shipkova M, Svinarov D, Mladenova A, Genova M, Wieland E, et al. Analysis of ITPA phenotype-genotype correlation in the Bulgarian population revealed a novel gene variant in exon 6. Ther Drug Monit 2007;29:6-10. (Pubitemid 46279870)
90. Maeda T, Sumi S, Ueta A, Ohkubo Y, Ito T, Marinaki AM, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency in the Japanese population. Mol Genet Metab 2005;85:271-9. (Pubitemid 41074110)
91. Cao H, Hegele RA. DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency. J Hum Genet 2002;47:620-2. (Pubitemid 36083264)
92. Arenas M, Duley J, Sumi S, Sanderson J, Marinaki A. The ITPA c.94C.A and g.IVS2121A.C sequence variants contribute to missplicing of the ITPA gene. Biochim Biophys Acta 2007;1772:96-102. (Pubitemid 44960729)
93. Stepchenkova EI, Tarakhovskaya ER, Spitler K, Frahm C, Menezes MR, Simone PD, et al. Functional study of the P32T ITPA variant associated with drug sensitivity in humans. J Mol Biol 2009;392:602-13.
94. Bierau J, Lindhout M, Bakker JA. Pharmacogenetic significance of inosine triphosphatase. Pharmacogenomics 2007;8: 1221-8. (Pubitemid 47578231)
95. Stocco G, Cheok MH, Crews KR, Dervieux T, French D, Pei D, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009;85:164-72.
96. Fraser JH, Meyers H, Henderson JF, Brox LW, McCoy EE. Individual variation in inosine triphosphate accumulation in human erythrocytes. Clin Biochem 1975;8:353-64.
97. Hitomi Y, Cirulli ET, Fellay J, McHutchison JG, Thompson AJ, Gumbs CE, et al. Inosine triphosphate protects against ribavirin-induced ATP loss by restoring adenylosuccinate synthase function. Gastroenterology 2011;140:1314-21.
98. Thompson AJ, Fellay J, Patel K, Tillmann HL, Naggie S, Ge D, et al. Variants in the ITPA gene protect against ribavirininduced hemolytic anemia and decrease the need for ribavirin dose reduction. Gastroenterology 2010;139:1181-9.
99. Thompson AJ, Santoro R, Piazzolla V, Clark PJ, Naggie S, Tillmann HL, et al. Inosine triphosphatase genetic variants are protective against anemia during antiviral therapy for HCV2/ 3 but do not decrease dose reductions of RBV or increase SVR. Hepatology 2011;53:389-95.
100. Ochi H, Maekawa T, Abe H, Hayashida Y, Nakano R, Kubo M, et al. ITPA polymorphism affects ribavirin-induced anemia and outcome of therapy -a genome-wide study of Japanese HCV patients. Gastroenterology 2010;139:1190-7.
101. Sakamoto N, Tanaka Y, Nakagawa M, Yatsuhashi H, Nishiguchi S, Enomoto N, et al. ITPA gene variant protects against anemia induced by PEGylated interferon-a and ribavirin therapy for Japanese patients with chronic hepatitis C. Hepatol Res 2010;40:1063-71.
102. Suzuki F, Suzuki Y, Akuta N, Sezaki H, Hirakawa M, Kawamura Y, et al. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir. Hepatology 2011;53:415-21.